[시장보고서]알레르기 및 자가면역질환 진단 시장 규모, 점유율, 동향 분석 보고서 : 제품 및 서비스별, 검사 유형별, 진단 유형별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

알레르기 및 자가면역질환 진단 시장 규모, 점유율, 동향 분석 보고서 : 제품 및 서비스별, 검사 유형별, 진단 유형별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Allergy And Autoimmune Disease Diagnostics Market Size, Share & Trends Analysis Report By Product & Service (Allergy Diagnostics), By Test Type, By Diagnostics Type, By End Use, By Region, And Segment Forecasts, 2025 - 2033

상품코드 : 1790425

리서치사 : Grand View Research

발행일 : 2025년 07월

페이지 정보 : 영문 136 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,950

￦ 8,575,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950

￦ 10,017,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950

￦ 12,899,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

알레르기 및 자가면역질환 진단 시장 개요

알레르기 및 자가면역질환 진단 세계 시장 규모는 2024년에 113억 8,000만 달러로 평가되었습니다. 2033년에는 250억 2,000만 달러에 달하고, 2025-2033년 5.41%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다. 이 시장은 알레르기 반응, 자가면역질환 등 다양한 면역 관련 질환의 검출 및 모니터링에 대응하고 있습니다.

만성 면역질환의 유병률 증가, 일반인 및 임상의의 인식 증가, 면역 분석 및 분자 플랫폼 등 진단 기법의 기술적 향상 등이 성장을 뒷받침하고 있습니다. 진단의 정확성, 속도, 접근성을 향상시키기 위한 지속적인 노력, 특히 포인트 오브 케어(Point of Care) 형식과 멀티플렉스 검사는 이러한 상황을 크게 바꾸고 있습니다. 실험실 인프라의 확장, 디지털 도구의 통합, 개인화된 면역 진단에 대한 관심은 질병의 조기 발견과 장기적인 관리 전략에 기여하고 있습니다. 바이오마커 연구와 AI 기반 분석의 혁신은 복잡한 자가면역 프로파일의 진단 정확도를 더욱 높여줄 것으로 기대됩니다.

미국 질병예방통제센터(CDC)가 2023년 1월 보도자료를 통해 발표한 2021년 국민건강조사(NHIS)에 따르면, 미국 성인 3명 중 1명, 어린이 4명 중 1명 이상이 계절성 알레르기, 습진, 음식 알레르기를 앓고 있는 것으로 보고됐습니다. 성인과 어린이의 약 6%가 식품 알레르기를 앓고 있으며, 그 비율은 다른 인종 및 민족 그룹에 비해 비 히스패닉계 흑인에서 현저하게 높은 것으로 나타났습니다. 이러한 수치는 다양한 인구 집단에서 알레르기 관련 질환에 대한 진단 수요가 증가하고 있음을 반영하며, 알레르기 및 자가면역질환 진단 의약품 업계에서 보다 정확하고 종합적인 검사 접근법의 필요성을 강조하고 있습니다.

또한, 이 시장에서는 재택 검사 및 분산형 검사 솔루션의 통합이 진행되어 기존 임상 환경을 넘어 진단에 대한 폭넓은 접근이 가능해졌습니다. 진단약 개발 기업, 공중보건기관, 민간 제공업체 간의 협력으로 지역 보건소 및 약국에서의 검사 이용이 강화되고 있습니다. 이러한 발전과 더불어 면역학 연구에 대한 투자 증가와 국가 의료 프로그램의 진단 적용 범위 확대로 인해 알레르기 및 자가면역 질환 진단 시장은 향후 몇 년 동안 그 입지를 강화할 것으로 예측됩니다.

기업 분류
전략 매핑
- 신제품 및 신규 서비스 발매
- 파트너십
- 취득
- 협업
- 자금조달
주요 기업의 시장 점유율 분석(2024년)
기업 히트맵 분석
기업 개요
- THERMO FISHER SCIENTIFIC, INC.
- HYCOR BIOMEDICAL
- EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG(PERKINELMER, INC.)
- OMEGA DIAGNOSTICS GROUP PLC
- LINCOLN DIAGNOSTICS, INC.
- AESKU.GROUP GMBH
- MINARIS MEDICAL AMERICA, INC.
- HOB BIOTECH GROUP CORP., LTD.
- DASIT GROUP SPA
- R-BIOPHARM AG
- BIOMERIEUX
- SIEMENS HEALTHCARE GMBH
- HOFFMANN-LA ROCHE LTD
- ABBOTT
- BECKMAN COULTER, INC.
- DANAHER CORPORATION
- QUEST DIAGNOSTICS
- NOVA DIAGNOSTICS PTE LTD.

LSH

영문 목차

영문목차

Allergy And Autoimmune Disease Diagnostics Market Summary

The global allergy and autoimmune disease diagnostics market size was estimated at USD 11.38 billion in 2024 and is projected to reach USD 25.02 billion by 2033, growing at a CAGR of 5.41% from 2025 to 2033. This market addresses the detection and monitoring of immune-related conditions, spanning a wide range of allergic reactions and autoimmune disorders.

Growth is being supported by the rising incidence of chronic immune conditions, greater public and clinical awareness, and technological improvements in diagnostic modalities such as immunoassays and molecular platforms. Ongoing efforts to improve diagnostic accuracy, speed, and accessibility, especially through point-of-care formats and multiplex testing, are reshaping the landscape. Expanding laboratory infrastructure, integration of digital tools, and interest in personalized immunodiagnostics are contributing to early disease detection and long-term management strategies. Innovations in biomarker research and AI-driven analysis are expected to further support diagnostic precision in complex autoimmune profiles.

According to the National Health Interview Survey (NHIS), 2021, published by the U.S. Centers for Disease Control and Prevention (CDC) in a press release dated January 2023, nearly 1 in 3 adults and more than 1 in 4 children in the U.S. reported having a seasonal allergy, eczema, or food allergy. Around 6% of both adults and children suffer from a food allergy, with the rate being notably higher among Black, non-Hispanic individuals compared to other racial and ethnic groups. These figures reflect the growing diagnostic demand for allergy-related conditions across diverse populations, emphasizing the need for more accurate and inclusive testing approaches in the allergy and autoimmune disease diagnostics industry.

In addition, the market is witnessing greater integration of home-based and decentralized testing solutions, enabling broader access to diagnostics beyond traditional clinical settings. Collaborations between diagnostic developers, public health agencies, and private providers are enhancing the availability of tests in community health centers and pharmacies. These developments, combined with rising investments in immunology research and the expansion of diagnostic coverage under national health programs, are expected to strengthen the position of the allergy and autoimmune disease diagnostics market over the coming years.

Global Allergy And Autoimmune Disease Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global allergy and autoimmune disease diagnostics market report based on product and service, diagnostics type, test type, end use, and region:

Product and Service Outlook (Revenue, USD Million, 2021 - 2033)
Allergy Diagnostics
- Instruments
- Consumables
- Services
Autoimmune Disease Diagnostics
- Instruments
- Consumables
- Services
Test Type Outlook (Revenue, USD Million, 2021 - 2033)
Allergy Diagnostics
- In vivo Test
- Skin Prick Test
- Intradermal Test
- Patch Test
- In vitro Test
- Autoimmune Disease Diagnostics
- Antinuclear Antibody Tests
- Autoantibody Tests
- C-reactive Protein (CRP)
- Complete Blood Count (CBC)
- Urinalysis
- Others
Diagnostics Type Outlook (Revenue, USD Million, 2021 - 2033)
Allergy Diagnostics
- Food
- Dairy Products
- Poultry Products
- Tree Nuts
- Peanuts
- Shellfish
- Wheat
- Soys
- Other Food Allergens
- Inhaled
- Drug
- Other Allergens
Autoimmune Disease Diagnostics
- Systemic Autoimmune Disease Diagnostics
- Rheumatoid Arthritis
- Ankylosing Spondylitis
- Systemic Lupus Erythematosus (SLE)
- Others
- Localized Autoimmune Disease Diagnostics
- Multiple Sclerosis
- Type 1 Diabetes
- Hashimoto's Thyroiditis
- Idiopathic Thrombocytopenic Purpura
- Others
End Use Outlook (Revenue, USD Million, 2021 - 2033)
Allergy Diagnostics
- Hospitals & Clinics
- Diagnostics Laboratories
- Research Institutions
- Others
Autoimmune Diagnostics
- Hospitals & Clinics
- Diagnostics Laboratories
- Research Institutions
- Others
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
- U.S.
- Canada
- Mexico
Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
Latin America
- Brazil
- Argentina
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait

Chapter 1. Allergy and Autoimmune Disease Diagnostics Market: Methodology and Scope

1.1. Market Segmentation and Scope
- 1.1.1. Segment Definitions
  - 1.1.1.1. Product and Service Segment
  - 1.1.1.2. Test Type Segment
  - 1.1.1.3. Diagnostics Type Segment
  - 1.1.1.4. End Use segment
1.2. Regional Scope
1.3. Estimates and Forecast Timeline
1.4. Objectives
- 1.4.1. Objective - 1
- 1.4.2. Objective - 2
- 1.4.3. Objective - 3
1.5. Research Methodology
1.6. Information Procurement
- 1.6.1. Purchased Database
- 1.6.2. GVR's Internal Database
- 1.6.3. Secondary Sources
- 1.6.4. Primary Research
1.7. Information or Data Analysis
- 1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
- 1.9.1. Commodity Flow Analysis
1.10. List of Secondary Sources
1.11. List of Abbreviations

Chapter 2. Allergy and Autoimmune Disease Diagnostics Market: Executive Summary

2.1. Market Snapshot
2.2. Product and Service and Test type Snapshot
2.3. Diagnostics Type Snapshot
2.4. End Use Snapshot
2.5. Competitive Landscape Snapshot

Chapter 3. Allergy and Autoimmune Disease Diagnostics Market Variables, Trends, & Scope

3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
- 3.2.1. Parent Market Outlook
- 3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers Analysis
- 3.4.1. Rising Prevalence of Immune-Related Disorders
- 3.4.2. Shift Toward Early and Personalized Diagnosis
- 3.4.3. Expansion of Decentralized and Home-Based Testing
3.5. Market Restraint Analysis
- 3.5.1. High Cost of Advanced Diagnostic Technologies
- 3.5.2. Underdiagnosis and Limited Awareness in Emerging Markets:
- 3.5.3. Regulatory and Reimbursement Barriers
3.6. Porter's Five Forces Analysis
3.7. PESTLE Analysis
3.8. Pipeline Analysis

Chapter 4. Allergy and Autoimmune Disease Diagnostics Market: Product and Service Estimates & Trend Analysis

4.1. Allergy and Autoimmune Disease Diagnostics Market: Product and Service Movement Analysis
4.2. Allergy Diagnostics
- 4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.2.2. Instruments
  - 4.2.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.2.3. Consumables
  - 4.2.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.2.4. Services
  - 4.2.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.3. Autoimmune Disease Diagnostics
- 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.3.2. Instruments
  - 4.3.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.3.3. Consumables
  - 4.3.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.3.4. Services
  - 4.3.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Allergy and Autoimmune Disease Diagnostics Market: Test Type Estimates & Trend Analysis

5.1. Allergy and Autoimmune Disease Diagnostics Market: Test Type Movement Analysis
5.2. Allergy Diagnostics
- 5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.2.2. In vivo Test
  - 5.2.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 5.2.2.2. Skin Prick Test
    - 5.2.2.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 5.2.2.3. Intradermal Test
    - 5.2.2.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 5.2.2.4. Patch Test
    - 5.2.2.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.2.3. In vitro Test
  - 5.2.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.2.4. Autoimmune Disease Diagnostics
  - 5.2.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 5.2.4.2. 'Antinuclear Antibody Tests
    - 5.2.4.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 5.2.4.3. Autoantibody Tests
    - 5.2.4.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 5.2.4.4. C-reactive Protein (CRP)
    - 5.2.4.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 5.2.4.5. Complete Blood Count (CBC)
    - 5.2.4.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 5.2.4.6. Urinalysis
    - 5.2.4.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 5.2.4.7. Others
    - 5.2.4.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Allergy and Autoimmune Disease Diagnostics Market: Diagnostics Type Estimates & Trend Analysis

6.1. Allergy and Autoimmune Disease Diagnostics Market: Technology Movement Analysis
6.2. Allergy Diagnostics
- 6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.2.2. Food
  - 6.2.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 6.2.2.2. Dairy Products
    - 6.2.2.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 6.2.2.3. Poultry Products
    - 6.2.2.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 6.2.2.4. Tree Nuts
    - 6.2.2.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 6.2.2.5. Peanuts
    - 6.2.2.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 6.2.2.6. Shellfish
    - 6.2.2.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 6.2.2.7. Wheat
    - 6.2.2.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 6.2.2.8. Soys
    - 6.2.2.8.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 6.2.2.9. Other Food Allergens
    - 6.2.2.9.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.2.3. Inhaled
  - 6.2.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.2.4. Drug
  - 6.2.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.2.5. Other Allergens
  - 6.2.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.3. Autoimmune Disease Diagnostics
- 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3.2. Systemic Autoimmune Disease Diagnostics
  - 6.3.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 6.3.2.2. Rheumatoid Arthritis
    - 6.3.2.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 6.3.2.3. Ankylosing Spondylitis
    - 6.3.2.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 6.3.2.4. Systemic Lupus Erythematosus (SLE)
    - 6.3.2.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 6.3.2.5. Others
    - 6.3.2.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3.3. Localized Autoimmune Disease Diagnostics
  - 6.3.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 6.3.3.2. Multiple Sclerosis
    - 6.3.3.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 6.3.3.3. Type 1 Diabetes
    - 6.3.3.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 6.3.3.4. Hashimoto's Thyroiditis
    - 6.3.3.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 6.3.3.5. Idiopathic Thrombocytopenic Purpura
    - 6.3.3.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 6.3.3.6. Others
    - 6.3.3.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Allergy and Autoimmune Disease Diagnostics Market: End Use Estimates & Trend Analysis

7.1. Allergy and Autoimmune Disease Diagnostics Market: End Use Movement Analysis
7.2. Allergy Diagnostics
- 7.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.2.2. Hospitals & Clinics
  - 7.2.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.2.3. Diagnostics Laboratories
  - 7.2.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.2.4. Research Institutions
  - 7.2.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.2.5. Others
  - 7.2.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
7.3. Autoimmune Diagnostics
- 7.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.2. Hospitals & Clinics
  - 7.3.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.3. Diagnostics Laboratories
  - 7.3.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.4. Research Institutions
  - 7.3.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.5. Others
  - 7.3.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Allergy and Autoimmune Disease Diagnostics Market: Regional Business Analysis

8.1. Regional Market Snapshot
8.2. North America
- 8.2.1. North America Allergy and Autoimmune Disease Diagnostics Market Estimates And Forecast, 2021 - 2033 (USD Million)
- 8.2.2. U.S.
  - 8.2.2.1. U.S. Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
  - 8.2.2.2. Key Country Dynamics
  - 8.2.2.3. Regulatory Framework
  - 8.2.2.4. Reimbursement Scenario
  - 8.2.2.5. Competitive Scenario
- 8.2.3. Canada
  - 8.2.3.1. Canada Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
  - 8.2.3.2. Key Country Dynamics
  - 8.2.3.3. Regulatory Framework
  - 8.2.3.4. Reimbursement Scenario
  - 8.2.3.5. Competitive Scenario
- 8.2.4. Mexico
  - 8.2.4.1. Mexico Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
  - 8.2.4.2. Key Country Dynamics
  - 8.2.4.3. Regulatory Framework
  - 8.2.4.4. Reimbursement Scenario
  - 8.2.4.5. Competitive Scenario
8.3. Europe
- 8.3.1. Europe Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
- 8.3.2. UK
  - 8.3.2.1. UK Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
  - 8.3.2.2. Key Country Dynamics
  - 8.3.2.3. Regulatory Framework
  - 8.3.2.4. Reimbursement Scenario
  - 8.3.2.5. Competitive Scenario
- 8.3.3. Germany
  - 8.3.3.1. Germany Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
  - 8.3.3.2. Key Country Dynamics
  - 8.3.3.3. Regulatory Framework
  - 8.3.3.4. Reimbursement Scenario
  - 8.3.3.5. Competitive Scenario
- 8.3.4. Spain
  - 8.3.4.1. Spain Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
  - 8.3.4.2. Key Country Dynamics
  - 8.3.4.3. Regulatory Framework
  - 8.3.4.4. Reimbursement Scenario
  - 8.3.4.5. Competitive Scenario
- 8.3.5. France
  - 8.3.5.1. France Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
  - 8.3.5.2. Key Country Dynamics
  - 8.3.5.3. Regulatory Framework
  - 8.3.5.4. Reimbursement Scenario
  - 8.3.5.5. Competitive Scenario
- 8.3.6. Italy
  - 8.3.6.1. Italy Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
  - 8.3.6.2. Key Country Dynamics
  - 8.3.6.3. Regulatory Framework
  - 8.3.6.4. Reimbursement Scenario
  - 8.3.6.5. Competitive Scenario
- 8.3.7. Denmark
  - 8.3.7.1. Denmark Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
  - 8.3.7.2. Key Country Dynamics
  - 8.3.7.3. Regulatory Framework
  - 8.3.7.4. Reimbursement Scenario
  - 8.3.7.5. Competitive Scenario
- 8.3.8. Sweden
  - 8.3.8.1. Sweden Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
  - 8.3.8.2. Key Country Dynamics
  - 8.3.8.3. Regulatory Framework
  - 8.3.8.4. Reimbursement Scenario
  - 8.3.8.5. Competitive Scenario
- 8.3.9. Norway
  - 8.3.9.1. Norway Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
  - 8.3.9.2. Key Country Dynamics
  - 8.3.9.3. Regulatory Framework
  - 8.3.9.4. Reimbursement Scenario
  - 8.3.9.5. Competitive Scenario
8.4. Asia Pacific
- 8.4.1. Asia Pacific Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
- 8.4.2. Japan
  - 8.4.2.1. Japan Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
  - 8.4.2.2. Key Country Dynamics
  - 8.4.2.3. Regulatory Framework
  - 8.4.2.4. Reimbursement Scenario
  - 8.4.2.5. Competitive Scenario
- 8.4.3. China
  - 8.4.3.1. China Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
  - 8.4.3.2. Key Country Dynamics
  - 8.4.3.3. Regulatory Framework
  - 8.4.3.4. Reimbursement Scenario
  - 8.4.3.5. Competitive Scenario
- 8.4.4. India
  - 8.4.4.1. India Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
  - 8.4.4.2. Key Country Dynamics
  - 8.4.4.3. Regulatory Framework
  - 8.4.4.4. Reimbursement Scenario
  - 8.4.4.5. Competitive Scenario
- 8.4.5. South Korea
  - 8.4.5.1. South Korea Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
  - 8.4.5.2. Key Country Dynamics
  - 8.4.5.3. Regulatory Framework
  - 8.4.5.4. Reimbursement Scenario
  - 8.4.5.5. Competitive Scenario
- 8.4.6. Thailand
  - 8.4.6.1. Thailand Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
  - 8.4.6.2. Key Country Dynamics
  - 8.4.6.3. Regulatory Framework
  - 8.4.6.4. Reimbursement Scenario
  - 8.4.6.5. Competitive Scenario
- 8.4.7. Australia
  - 8.4.7.1. Australia Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
  - 8.4.7.2. Key Country Dynamics
  - 8.4.7.3. Regulatory Framework
  - 8.4.7.4. Reimbursement Scenario
  - 8.4.7.5. Competitive Scenario
8.5. Latin America
- 8.5.1. Latin America Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
- 8.5.2. Brazil
  - 8.5.2.1. Brazil Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
  - 8.5.2.2. Key Country Dynamics
  - 8.5.2.3. Regulatory Framework
  - 8.5.2.4. Reimbursement Scenario
  - 8.5.2.5. Competitive Scenario
- 8.5.3. Argentina
  - 8.5.3.1. Argentina Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
  - 8.5.3.2. Key Country Dynamics
  - 8.5.3.3. Regulatory Framework
  - 8.5.3.4. Reimbursement Scenario
  - 8.5.3.5. Competitive Scenario
8.6. MEA
- 8.6.1. MEA Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
- 8.6.2. South Africa
  - 8.6.2.1. South Africa Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
  - 8.6.2.2. Key Country Dynamics
  - 8.6.2.3. Regulatory Framework
  - 8.6.2.4. Reimbursement Scenario
  - 8.6.2.5. Competitive Scenario
- 8.6.3. Saudi Arabia
  - 8.6.3.1. Saudi Arabia Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
  - 8.6.3.2. Key Country Dynamics
  - 8.6.3.3. Regulatory Framework
  - 8.6.3.4. Reimbursement Scenario
  - 8.6.3.5. Competitive Scenario
- 8.6.4. UAE
  - 8.6.4.1. UAE Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
  - 8.6.4.2. Key Country Dynamics
  - 8.6.4.3. Regulatory Framework
  - 8.6.4.4. Reimbursement Scenario
  - 8.6.4.5. Competitive Scenario
- 8.6.5. Kuwait
  - 8.6.5.1. Kuwait Allergy and Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
  - 8.6.5.2. Key Country Dynamics
  - 8.6.5.3. Regulatory Framework
  - 8.6.5.4. Reimbursement Scenario
  - 8.6.5.5. Competitive Scenario

Chapter 9. Competitive Landscape

9.1. Company Categorization
9.2. Strategy Mapping
- 9.2.1. New Product and Service Launch
- 9.2.2. Partnerships
- 9.2.3. Acquisition
- 9.2.4. Collaboration
- 9.2.5. Funding
9.3. Key Company Market Share Analysis, 2024
9.4. Company Heat Map Analysis
9.5. Company Profiles
- 9.5.1. THERMO FISHER SCIENTIFIC, INC.
  - 9.5.1.1. Company Overview
  - 9.5.1.2. Financial Performance
  - 9.5.1.3. Product and Service Benchmarking
  - 9.5.1.4. Strategic Initiatives
- 9.5.2. HYCOR BIOMEDICAL
  - 9.5.2.1. Company Overview
  - 9.5.2.2. Financial Performance
  - 9.5.2.3. Product and Service Benchmarking
  - 9.5.2.4. Strategic Initiatives
- 9.5.3. EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG (PERKINELMER, INC.)
  - 9.5.3.1. Company Overview
  - 9.5.3.2. Financial Performance
  - 9.5.3.3. Product and Service Benchmarking
  - 9.5.3.4. Strategic Initiatives
- 9.5.4. OMEGA DIAGNOSTICS GROUP PLC
  - 9.5.4.1. Company Overview
  - 9.5.4.2. Financial Performance
  - 9.5.4.3. Product and Service Benchmarking
  - 9.5.4.4. Strategic Initiatives
- 9.5.5. LINCOLN DIAGNOSTICS, INC.
  - 9.5.5.1. Company Overview
  - 9.5.5.2. Financial Performance
  - 9.5.5.3. Product and Service Benchmarking
  - 9.5.5.4. Strategic Initiatives
- 9.5.6. AESKU.GROUP GMBH
  - 9.5.6.1. Company Overview
  - 9.5.6.2. Financial Performance
  - 9.5.6.3. Product and Service Benchmarking
  - 9.5.6.4. Strategic Initiatives
- 9.5.7. MINARIS MEDICAL AMERICA, INC.
  - 9.5.7.1. Company Overview
  - 9.5.7.2. Financial Performance
  - 9.5.7.3. Product and Service Benchmarking
  - 9.5.7.4. Strategic Initiatives
- 9.5.8. HOB BIOTECH GROUP CORP., LTD.
  - 9.5.8.1. Company Overview
  - 9.5.8.2. Financial Performance
  - 9.5.8.3. Product and Service Benchmarking
  - 9.5.8.4. Strategic Initiatives
- 9.5.9. DASIT GROUP SPA
  - 9.5.9.1. Company Overview
  - 9.5.9.2. Financial Performance
  - 9.5.9.3. Product and Service Benchmarking
  - 9.5.9.4. Strategic Initiatives
- 9.5.10. R-BIOPHARM AG
  - 9.5.10.1. Company Overview
  - 9.5.10.2. Financial Performance
  - 9.5.10.3. Product and Service Benchmarking
  - 9.5.10.4. Strategic Initiatives
- 9.5.11. BIOMERIEUX
  - 9.5.11.1. Company Overview
  - 9.5.11.2. Financial Performance
  - 9.5.11.3. Product and Service Benchmarking
  - 9.5.11.4. Strategic Initiatives
- 9.5.12. SIEMENS HEALTHCARE GMBH
  - 9.5.12.1. Company Overview
  - 9.5.12.2. Financial Performance
  - 9.5.12.3. Product and Service Benchmarking
  - 9.5.12.4. Strategic Initiatives
- 9.5.13. HOFFMANN-LA ROCHE LTD
  - 9.5.13.1. Company Overview
  - 9.5.13.2. Financial Performance
  - 9.5.13.3. Product and Service Benchmarking
  - 9.5.13.4. Strategic Initiatives
- 9.5.14. ABBOTT
  - 9.5.14.1. Company Overview
  - 9.5.14.2. Financial Performance
  - 9.5.14.3. Product and Service Benchmarking
  - 9.5.14.4. Strategic Initiatives
- 9.5.15. BECKMAN COULTER, INC.
  - 9.5.15.1. Company Overview
  - 9.5.15.2. Financial Performance
  - 9.5.15.3. Product and Service Benchmarking
  - 9.5.15.4. Strategic Initiatives
- 9.5.16. DANAHER CORPORATION
  - 9.5.16.1. Company Overview
  - 9.5.16.2. Financial Performance
  - 9.5.16.3. Product and Service Benchmarking
  - 9.5.16.4. Strategic Initiatives
- 9.5.17. QUEST DIAGNOSTICS
  - 9.5.17.1. Company Overview
  - 9.5.17.2. Financial Performance
  - 9.5.17.3. Product and Service Benchmarking
  - 9.5.17.4. Strategic Initiatives
- 9.5.18. NOVA DIAGNOSTICS PTE LTD.
  - 9.5.18.1. Company Overview
  - 9.5.18.2. Financial Performance
  - 9.5.18.3. Product and Service Benchmarking
  - 9.5.18.4. Strategic Initiatives

한글목차

목차

제1장 알레르기 및 자가면역질환 진단 시장 : 조사 방법과 범위

제2장 알레르기 및 자가면역질환 진단 시장 : 주요 요약

제3장 알레르기 및 자가면역질환 진단 시장 변수, 동향 및 범위

제4장 알레르기 및 자가면역질환 진단 시장 : 제품 및 서비스별 추정 및 동향 분석

제5장 알레르기 및 자가면역질환 진단 시장 : 검사 유형별 추정 및 동향 분석

제6장 알레르기 및 자가면역질환 진단 시장 : 진단 유형별 추정 및 동향 분석

제7장 알레르기 및 자가면역질환 진단 시장 : 최종 용도별 추정 및 동향 분석

제8장 알레르기 및 자가면역질환 진단 시장 : 지역별 비즈니스 분석

제9장 경쟁 구도